Publications by authors named "O Claude"

During nuclear fuel processing, workers can potentially be exposed to repeated inhalations of uranium compounds. Uranium nephrotoxicity is well documented after acute uranium intake, but it is controversial after long-term or protracted exposure. This study aims to analyze the nephrotoxicity threshold after repeated uranium exposure through upper airways and to investigate the resulting uranium biokinetics in comparison to reference models.

View Article and Find Full Text PDF
Article Synopsis
  • Hereditary pulmonary veno-occlusive disease (hPVOD) is caused by mutations in the GCN2 gene, which is linked to severe pulmonary hypertension.
  • Research involved creating mutant rat lines to study lung responses to amino acid deprivation, specifically after administering PEG-asparaginase (ASNase).
  • Findings showed increased inflammation in the lungs, changes in immune cell populations, and a lack of integrated stress response activation, suggesting insights into hPVOD mechanisms and immune system roles.
View Article and Find Full Text PDF

Background: Myocardial infarction (MI) induces a repair response that ultimately generates a stable fibrotic scar. Although the scar prevents cardiac rupture, an excessive profibrotic response impairs optimal recovery by promoting the development of noncontractile fibrotic areas. The mechanisms that lead to cardiac fibrosis are diverse and incompletely characterized.

View Article and Find Full Text PDF

There is currently no therapy to limit the development of cardiac fibrosis and consequent heart failure. We have recently shown that cardiac fibrosis post-myocardial infarction (MI) can be regulated by resident cardiac cells with a fibrogenic signature and identified by the expression of PW1 (Peg3). Here we identify αV-integrin (CD51) as an essential regulator of cardiac PW1 cells fibrogenic behavior.

View Article and Find Full Text PDF

Pulmonary veno-occlusive disease (PVOD) occurs in humans either as a heritable form (hPVOD) due to biallelic inactivating mutations of encoding GCN2) or as a sporadic form in older age (sPVOD). The chemotherapeutic agent mitomycin C (MMC) is a potent inducer of PVOD in humans and in rats (MMC-PVOD). Here, we compared human hPVOD and sPVOD, and MMC-PVOD pathophysiology at the histological, cellular, and molecular levels to unravel common altered pathomechanisms.

View Article and Find Full Text PDF